Eagle Pharmaceuticals Inc (NAS:EGRX)
$ 3.78 -0.03 (-0.79%) Market Cap: 48.98 Mil Enterprise Value: 104.92 Mil PE Ratio: 4.15 PB Ratio: 0.20 GF Score: 62/100

Eagle Pharmaceuticals Inc Announces Worldwide Licensing Agreement with Combioxin SA Corporate Call Transcript

Sep 09, 2021 / 12:30PM GMT
Release Date Price: $51.95 (+0.78%)
Operator

Good morning, everyone. My name is Britney, and I will be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals CAL02 Investor Call. (Operator Instructions) As a reminder, this conference call is being recorded today, September 9, 2021.

It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.

Lisa Wilson

Thank you, Britney. Welcome to Eagle Pharmaceuticals CAL02 investor event. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With us on today's call are Eagle's Chief Executive Officer, Scott Tarriff; and Chief Medical Officer, Dr. Judith Ng-Cashin; along with our guest speakers, Dr. Samareh Lajaunias, Managing Director of Combioxin SA and Dr. Andre Kalil from the University of Nebraska Medical Center. A webcast of this call can be accessed through the Investor's section of the Eagle website at eagleus.com.

Please note that we intend to take questions specific to CAL02 only on this call. Before we get started, I would like

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot